Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
J Biochem Mol Toxicol. 2021 Jun;35(6):1-13. doi: 10.1002/jbt.22764. Epub 2021 Mar 12.
Cyclosporine-A (CsA) is a powerful immunosuppressive agent and hepatotoxicity results from CsA treatment. This study aimed to elucidate the effectiveness of tyrosine kinase inhibitor nilotinib against CsA-induced hepatotoxicity and the underlying molecular mechanisms. Male Sprague-Dawley rats were allocated into four groups and received drugs for 28 days as follows: Control group: received vehicle, Nilotinib group: received nilotinib (20 mg/kg orally), CsA group: received CsA by subcutaneous injection (20 mg/kg daily), CsA-nilotinib: received nilotinib and CsA. Serum lactate dehydrogenase (LDH), liver function biomarkers, hepatic levels of oxidative stress biomarkers, nuclear factor erythroid-2 like-2 (Nrf2), total antioxidant capacity (TAC), interleukin-2 (IL-2), IL-1β, IL-6, and cytochrome-C were assessed. Additionally, the protein levels and mRNA expression of Bcl2 associated X protein (Bax), caspase-3, nuclear factor-κB (NF-κB), hemoxygenase-1 (HO-1) were measured. Moreover, liver tissues were assessed histopathologically using hematoxylin-eosin and Masson trichrome stain. Nilotinib treatment decreased serum LDH, alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltransferase (γ-GT), hepatic malondialdehyde, and cytochrome-C. It also increased superoxide dismutase, reduced glutathione, glutathione reductase, glutathione peroxidase, glutathione-S-transferase (GST), TAC, and Nrf2 compared to CsA-injected rats. In addition, nilotinib decreased NF-κB, IL-1β, IL-6, Bax, and caspase-3, while elevated IL-2 and immunoexpression of HO-1. Additionally, mRNA expression of Bax and caspase-3 was elevated and that of HO-1 and inhibitory protein κB-α was reduced in the nilotinib-treated group. Moreover, nilotinib significantly attenuated CsA-induced histopathological alterations. Nilotinib may have a promising role as a hepato-protective through its antiapoptotic, antioxidant, and anti-inflammatory effects.
环孢素 A(CsA)是一种强效的免疫抑制剂,其治疗会导致肝毒性。本研究旨在阐明酪氨酸激酶抑制剂尼罗替尼对 CsA 诱导的肝毒性的治疗效果及其潜在的分子机制。雄性 Sprague-Dawley 大鼠被分为四组,并接受以下药物治疗 28 天:对照组:给予载体;尼罗替尼组:给予尼罗替尼(20mg/kg 口服);CsA 组:每天皮下注射 CsA(20mg/kg);CsA-尼罗替尼组:给予尼罗替尼和 CsA。检测血清乳酸脱氢酶(LDH)、肝功能生物标志物、肝氧化应激生物标志物、核因子红细胞 2 样 2(Nrf2)、总抗氧化能力(TAC)、白细胞介素-2(IL-2)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和细胞色素-C 的水平。此外,还测量了 Bcl2 相关 X 蛋白(Bax)、半胱天冬酶-3、核因子-κB(NF-κB)、血红素加氧酶-1(HO-1)的蛋白水平和 mRNA 表达。此外,用苏木精-伊红和 Masson 三色染色法对肝组织进行组织病理学评估。尼罗替尼治疗降低了血清 LDH、丙氨酸氨基转移酶、天冬氨酸氨基转移酶和γ-谷氨酰转移酶(γ-GT)、肝丙二醛和细胞色素-C。与 CsA 注射大鼠相比,它还增加了超氧化物歧化酶、还原型谷胱甘肽、谷胱甘肽还原酶、谷胱甘肽过氧化物酶、谷胱甘肽-S-转移酶(GST)、TAC 和 Nrf2。此外,尼罗替尼降低了 NF-κB、IL-1β、IL-6、Bax 和半胱天冬酶-3,而升高了 IL-2 和 HO-1 的免疫表达。此外,尼罗替尼治疗组 Bax 和半胱天冬酶-3 的 mRNA 表达增加,HO-1 和抑制性κB-α的 mRNA 表达减少。此外,尼罗替尼显著减轻了 CsA 诱导的组织病理学改变。尼罗替尼可能通过其抗凋亡、抗氧化和抗炎作用发挥有前途的肝保护作用。